Bioextrax AB (BIOEX) AI Stock Analysis

0 Followers

Bioextrax AB

(Nasdaq OMX AB:BIOEX)

Select Model

Rating:49Neutral

Price Target:SEK 2.50▼(-6.37% Downside)

Action:reiterated

Date:11/13/26

The score is held down primarily by weak financial performance—persistent losses, negative gross profit in most years, and ongoing (accelerating) cash burn despite a debt-free balance sheet. Technicals are a partial offset with price above key moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add near-term risk. Valuation is also constrained by negative earnings (negative P/E) and no provided dividend yield.

Positive Factors

Debt-free balance sheetA debt-free balance sheet reduces refinancing exposure and interest obligations, giving Bioextrax greater flexibility while it develops its products. This structure can help preserve strategic options during periods of weak profitability, although ongoing losses still threaten capital strength.

Negative Factors

Very small, declining revenueSmall and declining revenue limits Bioextrax’s ability to absorb operating expenses and demonstrates that commercial scale has not yet been established. Continued contraction would make it harder to fund product development internally and could delay the transition toward a sustainable operating model.

Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 131.31M
Dividend Yield: ―
Average Volume (3M): 70.38K
Price to Earnings (P/E): -6.2
Beta (1Y): 0.85
Revenue Growth: -37.50%
EPS Growth: 1.01%
Country: Sweden
Employees: 14
Sector: Industrials
Sector Strength: 63
Industry: Biotechnology

Bioextrax AB Business Overview & Revenue Model

Company Description

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules...

Bioextrax AB Financial Statement Overview

Summary

Financial performance is weak overall: revenue is very small and declining in the latest periods, gross profit is negative in most years, and operating/net losses are consistently deep. Cash flow is a major risk with negative operating cash flow and free cash flow every year and an accelerating cash burn in 2025. The main offsetting strength is a conservatively financed balance sheet with zero debt, though equity has been trending down due to ongoing losses.

Income Statement

12Very Negative

Balance Sheet

55Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	360.00K	757.00K	515.00K	2.06M	395.00K	275.76K
Gross Profit	-14.84M	-16.43M	-915.00K	718.00K	-18.64M	-11.29M
EBITDA	-14.16M	-17.24M	-16.18M	-20.65M	-18.19M	-10.18M
Net Income	-14.24M	-17.70M	-17.34M	-21.51M	-18.67M	-10.53M
Balance Sheet
Total Assets	14.49M	24.73M	29.00M	22.52M	37.92M	12.64M
Cash, Cash Equivalents and Short-Term Investments	7.39M	3.93M	17.27M	13.40M	27.53M	8.98M
Total Debt	0	0	0	0	0	0
Total Liabilities	2.51M	3.51M	2.94M	1.98M	6.15M	5.14M
Stockholders Equity	11.98M	21.21M	26.06M	20.54M	31.77M	7.50M
Cash Flow
Free Cash Flow	-23.61M	-26.20M	-18.99M	-24.41M	-24.38M	-9.45M
Operating Cash Flow	-23.34M	-26.05M	-18.78M	-23.31M	-17.60M	-8.48M
Investing Cash Flow	-277.00K	-152.00K	-215.00K	-1.10M	-6.78M	-975.13K
Financing Cash Flow	12.58M	12.86M	22.86M	10.28M	42.94M	16.38M

Bioextrax AB Technical Analysis

Technical Analysis SentimentPositive

Last Price2.67

Price Trends

50DMA2.33Positive

100DMA2.40Positive

200DMA2.53Positive

Market Momentum

MACD0.06Negative

RSI72.00Negative

STOCH75.06Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Positive. The current price of 2.67 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.33, and above the 200-day MA of 2.53, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 72.00 is Negative, neither overbought nor oversold. The STOCH value of 75.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (63)

Financial Indicators

SE:BIOEX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
SE:BIOEX	49Neutral	SEK 131.31M	-6.15	-116.56%	―	-37.50%	1.01%
SE:NXTCL	46Neutral	SEK 30.14M	-0.63	-81.23%	―	-4.02%	35.86%
SE:ANNX	44Neutral	SEK 77.94M	-2.05	―	―	―	7.33%
SE:SPAGO	42Neutral	SEK 36.09M	-1.13	-87.37%	―	-97.52%	31.31%
SE:BIOVIC.B	41Neutral	SEK 88.95M	-1.22	-75.51%	―	56.06%	63.95%
SE:XINT	39Underperform	SEK 120.58M	-2.39	245.07%	―	-38.46%	9.02%

* Industrials Sector Average

Performance Comparison

SE:BIOEX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:BIOEX	Bioextrax AB	2.67	0.56	26.78%
SE:XINT	Xintela AB	0.14	-0.11	-44.22%
SE:BIOVIC.B	Biovica International AB Class B	0.30	-0.28	-47.59%
SE:NXTCL	NextCell Pharma AB	0.24	-0.56	-69.81%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.07	-61.21%
SE:ANNX	Annexin Pharmaceuticals AB	9.04	-15.98	-63.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Bioextrax AB AI Stock Analysis